NCT06106308Phase 2Active not recruiting

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Study sponsor: Cardiff Oncology

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-04-16Estimated
Enrollment · participants110Actual
Source updated2026-11-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Nov 2026. After: 16 Apr 2027.

Check registry source

· 1 field changed

Actual enrollment decreased by 3 participants

Before: 113 participants (actual). After: 110 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview